Stock & Company Details
Zimmer Biomet Holdings Inc $ZBH
Price:
N/A
N/A
191M
$17B
52 Week High:
N/A
10 Day Average Volume:
N/A
21.63
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
ZBH technical indicators
Latest Zimmer Biomet Holdings Inc (ZBH) indicator readings as of 2026-10-09.
ZBH's 14-day RSI is 41.0, in neutral territory. At $89.14 it is trading 2.4% below its 200-day moving average of $91.32, and below its 50-day average of $95.61. Price sits in the middle of its Bollinger Bands ($85.64 to $98.07). ADX reads 22.0, sitting between trending and range-bound.
ZBH backtested strategy results
How 4 rule-based strategies performed on Zimmer Biomet Holdings Inc (ZBH) over recent history, last backtested 2026-09-10. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | +10.1% | 55% | 11 | -31.1% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -61.2% | 29% | 31 | -67.4% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | -43.1% | 28% | 29 | -49.7% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +15.0% | 45% | 20 | -27.0% |
Overview
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
Finance Bot
Ask your questions
Start by typing a question below.
